Different prognostic roles of tumor suppressor gene BAP1 in cancer: A systematic review with meta-analysis

• Published in: Genes chromosomes & cancer Vol. 55; no. 10; pp. 741 - 749
• Main Authors: Luchini, Claudio, Veronese, Nicola, Yachida, Shinichi, Cheng, Liang, Nottegar, Alessia, Stubbs, Brendon, Solmi, Marco, Capelli, Paola, Pea, Antonio, Barbareschi, Mattia, Fassan, Matteo, Wood, Laura D, Scarpa, Aldo
• Format: Journal Article
• Language: English
• Published: United States Blackwell Publishing Ltd 01.10.2016; Wiley Subscription Services, Inc
• Subjects: Female; Genes, Tumor Suppressor; Humans; Male; Mutation; Neoplasm Recurrence, Local - genetics; Neoplasm Recurrence, Local - mortality; Neoplasms - genetics; Neoplasms - mortality; Prognosis; PubMed; Risk Factors; Tumor Suppressor Proteins - genetics; Ubiquitin Thiolesterase - genetics
• ISSN: 1045-2257; 1098-2264
• DOI: 10.1002/gcc.22381

Biallelic inactivation of the tumor suppressor gene BRCA1‐associated protein 1 (BAP1) has been demonstrated in several cancers, but its prognostic role has not been completely explained. We aimed to investigate the risk associated with loss of BAP1 (BAP1‐) for all‐cause mortality, cancer‐specific mortality and recurrence of disease in subjects with cancer. PubMed and SCOPUS were searched from database inception until 09/15/2015 without language restrictions. Prospective studies reporting data on prognostic parameters in subjects with cancer, comparing participants with presence of BAP1 (BAP1+) vs. BAP1‐ were included. Data were summarized using risk ratios (RR) for number of deaths/recurrences and hazard ratios (HR) for time‐dependent risk related to BAP1‐ adjusted for potential confounders. From 261 hits, 12 studies (including 13 cohorts) with 3,447 participants (BAP1‐: n = 697; BAP1+: n = 2,750), with a median follow‐up over 60 months, were meta‐analyzed. Compared to BAP1+, BAP1‐ significantly increased all‐cause mortality, cancer‐specific mortality and risk of recurrence in all the tumor types analyzed, except for mesothelioma, in which the presence of BAP1 mutations correlates with a better prognosis. Furthermore, we demonstrated that BAP1 mutated colorectal and renal carcinomas are associated with high‐tumor grading (P < 0.0001), and that BAP1 mutated is more common in women than in men (P < 0.0001). In conclusion, on the basis of our meta‐analysis, we have demonstrated a peculiar role of BAP1 in influencing the prognosis in cancer. Thus, BAP1 could be considered as an important potential target for personalized medicine. © 2016 Wiley Periodicals, Inc.